3,420
Participants
Start Date
December 18, 2006
Primary Completion Date
October 7, 2014
Study Completion Date
July 26, 2022
Placebo
Denosumab
Administered as a subcutaneous injection
Non-steroidal aromatase inhibitor therapy
An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
Zoledronic Acid
5 mg zoledronic acid administered at a constant infusion rate
Standard of Care
Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Vienna
Research Site, Baden
Research Site, Wiener Neustadt
Research Site, Sankt Pölten
Research Site, Krems
Research Site, Linz
Research Site, Linz
Research Site, Steyr
Research Site, Wels
Research Site, Schärding
Research Site, Gmunden
Research Site, Vöcklabruck
Research Site, Ried
Research Site, Salzburg
Research Site, Braunau am Inn
Research Site, Innsbruck
Research Site, Hall in Tirol
Research Site, Kufstein
Research Site, Feldkirch
Research Site, Dornbirn
Research Site, Oberpullendorf
Research Site, Güssing
Research Site, Graz
Research Site, Graz
Research Site, Weiz
Research Site, Leoben
Research Site, Rottenmann
Research Site, Klagenfurt
Research Site, Sankt Veit an der Glan
Research Site, Wolfsberg
Research Site, Villach
Research Site, Villach
Research Site, Lienz
Research Site, Gävle
Research Site, Gothenburg
Research Site, Stockholm
Research Site, Stockholm
Research Site, Uppsala
Lead Sponsor
Austrian Breast and Colorectal Cancer Study Group
UNKNOWN
Amgen
INDUSTRY